Scleroderma: from pathophysiology to novel therapeutic approaches

Area of Science:

• Rheumatology
• Cellular and Molecular Medicine
• Pharmacology

Background:

• Systemic scleroderma (SSc) is a rare orphan disease with complex pathophysiology, hindering research and therapeutic development.
• Recent advances have improved understanding of growth factors, connective tissue physiology, and SSc's underlying mechanisms.
• Key factors in SSc pathophysiology include hypoxia, cellular stress, and interacting cytokines.

Purpose of the Study:

• To review recent advances in understanding SSc pathophysiology.
• To highlight the role of tyrosine kinases in regulating key cytokines and growth factors involved in SSc.
• To discuss novel therapeutic strategies targeting signaling pathways.

Main Methods:

• Literature review of recent research on SSc mechanisms.
• Analysis of the role of growth factors, cytokines, and signaling pathways in SSc.
• Investigation of emerging pharmacological compounds, specifically tyrosine kinase inhibitors.

Main Results:

• Tyrosine kinases regulate critical cytokines like transforming growth factor-beta and platelet-derived growth factor in SSc.
• Hypoxia and cellular stress are central to SSc pathophysiology, involving a network of cytokines.
• Novel tyrosine kinase inhibitors are being explored for SSc treatment.

Conclusions:

• Understanding SSc pathophysiology has advanced, revealing the importance of hypoxia, cellular stress, and specific signaling pathways.
• Tyrosine kinase inhibitors represent a promising therapeutic avenue for SSc by modulating key molecular targets.
• Further research into these novel compounds is crucial for developing effective treatments for this life-threatening disease.